Eurand is a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products using our innovative drug delivery technologies. The Company抯drug development efforts are based on three commercialized technology platforms; bioavailability enhancement of poorly soluble drugs, customized release and taste masked/fast dissolving formulations. Eurand has recently added a fourth technology platform, drug targeting, to its capabilities that, once commercialized, can be applied to small molecule and biotechnology derived products for improved drug delivery.

Eurand is dedicated to the continued development and commercialization of breakthrough technologies and products that better satisfy patients needs. To this end, the Company develops treatment options with superior safety, enhanced efficacy and convenient dosing.

Eurand is a global company with more than 500 employees. Its principal operating offices are in Milan, Italy. The Company has research, development and manufacturing facilities throughout the world including sites in Milan and Trieste, Italy; Dayton, Ohio (US) and Paris, France.

Eurand was founded in Milan Italy in 1969. From 1989-1999, Eurand was part of American Home Products Corporation (NYSE: AHP). The Company became independent in 1999 as the result of a leveraged buy out from AHPC (Wyeth NYSE: WYE) led by management and Warburg Pincus.